Measured Wealth Private Client Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$821K Sell
3,544
-75
-2% -$18.5K 0.21% 71
2026
Q2
$872K Sell
3,619
-82
-2% -$18K 0.21% 76
2026
Q1
$700K Sell
3,701
-242
-6% -$42.3K 0.19% 81
2025
Q4
$670K Sell
3,943
-705
-15% -$108K 0.18% 77
2025
Q3
$613K Sell
4,648
-207
-4% -$24.8K 0.17% 84
2025
Q2
$515K Buy
4,855
+1,554
+47% +$169K 0.15% 97
2025
Q1
$410K Buy
+3,301
New +$431K 0.13% 109

Other funds holding JAZZ

Measured Wealth Private Client Group's JAZZ Position: Q3 2026 in Review

Measured Wealth Private Client Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 2.1% in Q3 2026, selling an estimated $18.5K and leaving 3,544 shares worth $821K. The position accounts for 0.21% of the portfolio, ranked #71.

Measured Wealth Private Client Group first reported a position in JAZZ in Q1 2025 and has held it in 7 quarters since. The position peaked at $872K in Q2 2026. 672 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Measured Wealth Private Client Group held 3,544 shares of Jazz Pharmaceuticals worth $821K as of Q3 2026.
  • Measured Wealth Private Client Group sold 75 Jazz Pharmaceuticals shares in Q3 2026, an estimated $18.5K.
  • Jazz Pharmaceuticals made up 0.21% of Measured Wealth Private Client Group's portfolio in Q3 2026, its #71 holding.
  • Measured Wealth Private Client Group first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • Measured Wealth Private Client Group's Jazz Pharmaceuticals position peaked at $872K in Q2 2026.
  • 672 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q3 2026, filed 10 Nov 2026.